DALLAS, Aug. 12, 2014 /PRNewswire/ -- ProPath®, a leader in pathology services and an advocate for advancements in healthcare, reinforces commitment to quality and efficiency through partnership with Dako, an Agilent Technologies Company.
ProPath recently performed a head-to-head comparison study focusing on the accuracy and speed of two FDA-approved FISH (Fluorescence in situ hybridization) probe sets targeting the HER2 gene. Both kits are designed to detect amplification of the HER2 gene. The tests are used by oncologists to determine the optimal treatment regimen for women with breast cancer.
Based upon the results yielded by this comparative study, ProPath has elected to utilize the HER2 IQFISH pharmDx™ kit produced by Dako. As part of the study, ProPath processed and analyzed over 1,000 patient samples by each method. The results demonstrated that the HER2 IQFISH pharmDx™ platform resulted in better specimen preparation. The specimens produced using the Dako system were consistently of a significantly higher quality and required fewer corrective actions on the part of the technician.
In addition, the HER2 IQFISH pharmDx™ platform required less processing time, which resulted in a considerable reduction in the turnaround time for patient test results. Offering a time savings of approximately 16 hours, and a more streamlined workflow, the HER2 IQFISH pharmDx™ also enables the lab to function more efficiently.
"In our study, the HER2 IQFISH pharmDx™ platform provided significant advantages in terms of quality of the analysis and speed of reporting the test.", said Debra Cohen, Cytogenetics Manager at ProPath. "We are pleased to be able to offer this test to our physicians to help them manage their cancer patients." Cohen also noted that "the Dako platform is a nice addition to our large menu of oncology-related tests."
ProPath is dedicated to offering physicians and patients accurate and timely laboratory results. Dako's HER2 IQFISH pharmDx™ test fits well into ProPath's mission of providing highest quality pathology services.
ProPath® is a team of pathologists recruited from top-tier medical centers and academic institutions around the country. ProPath® has surrounded its physicians with an unsurpassed, internationally-recognized laboratory utilizing a proprietary tracking system for every patient specimen. As with all medical specialties, the quality of a cancer diagnosis is directly related to the education, talent and experience of the rendering physician. The ProPath® teams of board-certified and subspecialty-trained pathologists are the experts you want rendering your diagnosis. For more information about ProPath®, please visit ProPath.com. Also, follow us on Facebook and Twitter.
For Press Inquiries contact:
Marketing Manager, ProPath